ECMO for COVID-19 vs Influenza A H1N1 Associated ARDS

University of Turin, Italy308 enrolled

Overview

Objective: Veno-venous ECMO has been used as a rescue therapy for patients with severe ARDS associated to influenza A H1N1 and COVID19 viral pneumonia. Little is known about outcome of these patients who required extracorporeal support. Research question: To compare outcome of patients who required VV ECMO for Covid19 and H1N1 associated ARDS

Study Type

OBSERVATIONAL

Enrollment

308

Conditions

ARDS COVID-19 H1N1 Influenza

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * COVID-19 or influenza A H1N1 (suspected or confirmed) diagnosis * Severe ARDS (according to Berlin Definition) * VV ECMO * Invasive mechanical ventilation through endotracheal tube or tracheostomy Exclusion Criteria: • Age\<18 years

Locations (1)

University of Turin - Azienda Ospedaliera Città della Salute e della Scienza di Torino

Turin, Italy

Outcomes

Primary Outcomes

All cause mortality on day 60 after ECMO initiation

Time frame: 60 days

Secondary Outcomes

Hospital length of stay

Time frame: 90 days

ICU length of stay

Time frame: 90 days

Hospital mortality on day 90 after ECMO initiation

Time frame: 90 days

ECMO duration

Time frame: 90 days

ECMO associated hemorrhagic complications

Time frame: 60 days

ECMO associated mechanical complications

Time frame: 60 days

Invasive mechanical ventilation duration

Time frame: 90 days

ECMO related haemorrhagic complications

Time frame: 90 days

ECMO related mechanical complications

Time frame: 90 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.